Menu Search
Equities

Genfit SA

GNFT:PAR

Genfit SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)4.01
  • Today's Change-0.405 / -9.17%
  • Shares traded948.18k
  • 1 Year change-2.67%
  • Beta1.0687
Data delayed at least 15 minutes, as of Jun 14 2024 16:35 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Genfit SA had net income fall 21.81% from a loss of 23.72m to a larger loss of 28.89m despite a 43.70% increase in revenues from 26.57m to 38.18m.
Gross margin94.32%
Net profit margin-75.69%
Operating margin-69.62%
Return on assets-14.84%
Return on equity-35.57%
Return on investment-18.55%
More ▼

Cash flow in EURView more

In 2023, cash reserves at Genfit SA fell by 58.21m. However, Cash Flow from Investing totalled 2.23m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 55.43m for operations while cash used for financing totalled 5.10m.
Cash flow per share-0.5487
Price/Cash flow per share--
Book value per share1.36
Tangible book value per share0.3851
More ▼

Balance sheet in EURView more

Genfit SA has a Debt to Total Capital ratio of 50.80%, a lower figure than the previous year's 74.26%.
Current ratio2.94
Quick ratio2.94
Total debt/total equity1.03
Total debt/total capital0.5080
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.